> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rapport's Bipolar Mania Drug Beat Placebo By 3.1 Points, But Twice As Many Quit Treatment
- URL: https://www.bullished.co/rapports-bipolar-mania-drug-beat-placebo-by-3-1-points-but-twice-as-many-quit-treatment-f4fda96c/
- Published: 2026-10-20T10:21:29.000Z
- Updated: 2026-10-28T20:01:02.000Z
- Description: An 8-K shows RAP-219 met its main goal in a 253-adult mid-stage trial, with 24.6% stopping treatment versus 11.8% on placebo.
- Author: Matteo Parrino
- Tags: SEC Filings, RAPP, Industry: Healthcare

[Rapport Therapeutics](https://www.bullished.co/tag/rapp/) said its experimental drug RAP-219 met the main goal of a mid-stage trial in acute bipolar mania, with a [3.1-point placebo-adjusted improvement](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134d8k.htm?ref=bullished.co) on the Young Mania Rating Scale at Week 3 (p=0.045), according to an [8-K](https://www.bullished.co/learn/8-k-items-explained/) filed Tuesday. The company plans to meet the FDA in the first quarter of 2027 and expects to start two late-stage trials in the second half of 2027.

## What the trial showed

The randomized, double-blind trial, run in the United States, enrolled 253 adults with bipolar I disorder in an acute manic episode. Patients got 0.75 mg of RAP-219 daily or placebo for three weeks in an inpatient setting.

On the Young Mania Rating Scale, RAP-219 patients improved by a mean 15.4 points, versus 12.3 points on placebo. The placebo-adjusted gap grew over time: 0.9 at Week 1, 2.2 at Week 2 and 3.1 at Week 3.

The pre-specified secondary measure, a clinician rating of mania severity, improved by 0.4 points versus placebo (p=0.024). All 11 scale items favored the drug; irritability, thought content, disruptive-aggressive behavior and sexual interest reached nominal significance (p<0.05), meaning before any adjustment for multiple comparisons.

## Safety, and the dropout gap

Adverse events were similar: 51.6% on RAP-219 versus 52.8% on placebo. All were mild or moderate, and none were serious. Nausea was the only common event reported at least twice as often on the drug. The safety figures come from an interim database lock on September 16, 2026.

Still, 3.2% of RAP-219 patients stopped over an adverse event versus 0.8% on placebo. Overall, [31 patients (24.6%)](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134dex991.htm?ref=bullished.co) on the drug discontinued versus 15 (11.8%) on placebo.

The most common reason was withdrawal of consent: 16.7% on RAP-219 against 4.7% on placebo. Reasons included personal reasons, family reasons, wanting to leave the inpatient unit and worsening symptoms.

CEO Abraham N. Ceesay said the drug could offer "the first new mechanism of action for bipolar mania in decades."

## What comes next

Rapport plans an End-of-Phase 2 meeting with the FDA in the first quarter of 2027\. A slide in the [webcast deck](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134dex992.htm?ref=bullished.co) lists a higher 1.25 mg dose and ex-US sites among planned Phase 3 changes.

The company had $436.1 million in cash, equivalents and short-term investments as of June 30, 2026, which it expects to fund operations into the second half of 2029\. Initial long-term open-label data in focal onset seizures are expected in the fourth quarter of 2026.

RAPP closed at $28.60 on Monday, before the filing was accepted at 6:05 a.m. ET Tuesday.

Learn

- [Item 7.01: Regulation FD disclosure →](https://www.bullished.co/learn/8-k-items-explained/#item-701-regulation-fd-disclosure)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rapport Therapeutics, Inc. (RAPP)](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134d8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d185134dex991.htm — Rapport Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134dex991.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit d185134dex992.htm — Rapport Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0002012593/000119312526425647/d185134dex992.htm?ref=bullished.co) — SEC EDGAR

### More on Rapport Therapeutics

- [Rapport Therapeutics Prices $200 Million Share Sale At $21, Below Tuesday's $27.54 Price](https://www.bullished.co/rapport-therapeutics-prices-200-million-share-sale-at-21-below-tuesdays-27-54-price-8d01d92e/)

[All Rapport Therapeutics (RAPP) coverage →](https://www.bullished.co/tag/rapp/)